Stockreport

Capricor extends rally as FDA to review rejected cell therapy [Seeking Alpha]

Capricor Therapeutics, Inc.  (CAPR) 
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: capricor.com/investors
PDF Food and Drug Administration agreed to review the company's previously rejected lead candidate, Deramiocel, a cell therapy for patients with a rare disorder called Duche [Read more]